Nivolumab-AVD reduces the risk of disease progression compared to brentuximab vedotin-AVD in advanced Hodgkin lymphoma

PHE885 CAR-T cell therapy shows high response rates for r/r multiple myeloma in phase 1

HCC: Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL

Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

Teclistamab plus talquetamab targeting BCMA and GPRC5D shows promise in RRMM

AI-derived digital pathology-based biomarker predicts benefit of long-term ADT with RT in localised high-risk prostate cancer

Talquetamab plus daratumumab for RRMM: TRIMM-2 update

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer

NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres

NSIA and BVGH aim to improve patient outcomes and access to quality cancer care

Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer